Why choose apheresis platelet concentrates?

Infusionstherapie und Transfusionsmedizin

Volumn 23, Issue SUPPL. 1, 1996, Pages 24-29

  Andreu, G ^a   Angue M ^b   Calot, J P ^b   Coffe, C ^b   Cotte, C ^b   David, C ^b   Ferrer Lecoenr F ^b   Fontaine, O ^b   Gaschard, P ^b   Girard, A ^b   Hardy, E ^b   Hau, F ^b   Masse, M ^b   Michel, M ^b   Royer, D ^b   Schooneman, F ^b   Vicariot, M ^b   Villard, F ^b   Waller, C ^b  

^a HÔTEL DIEU   (France)

^b Hôpital Hôtel Dieu ^*

Author keywords

Apheresis platelets; Buffy coat platelets; Platelet collection methods; Platelet dose

Indexed keywords

EID: 0346377180     PISSN: 14245485     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Washitami Y, Irita Y, Yamamoto K, Shiraki H, Kiyokawa H, Maeda Y, Yoshinari M: Prevention of acquired defects in platelet function during blood processing. Transfusion 1988;28:571-575.
2. Fijnheer R, Pietersz RNT, deKorte D, Gouwerok CWN, Dekker WJA, Reesink HW, Roos D: Platelet activation during preparation of platelet concentrates: A comparison of the platelet-rich plasma and the buffy coat methods. Transfusion 1990;30:634-638.
3. Gmur J, von Felten A, Osterwalder B, Frick P: Delayed alloimmunization using random single-donor platelet transfusions: A prospective study in patients with leukemia. Blood 1983;62:473-479.
4. Hanson SR, Slichter SJ: Platelet kinetics in patients with bone marrow hypoplasia: Evidence for a fixed platelet requirement. Blood 1985;66:1105-1109.
5. Gmür J, Burger J, Schanz U, Fehr J, Schaffner A: Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia. Lancet 1991; 338:1223-1226.